Indirect Comparison Between Eltrombopag & Romiplostim
- Registration Number
- NCT01236014
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
An indirect comparison to compare the efficacy of eltrombopag versus romiplostim
- Detailed Description
An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
- Adults with ITP
- Pre-specified treatment
- Prospective clinical studies with at least 10 patients
Exclusion Criteria
- Adults with ITP for other reasons
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Romiplostim & standard of care Romiplostim - Eltrombopag & standard of care Eltrombopag - Standard of care Placebo -
- Primary Outcome Measures
Name Time Method Durable response: platelet count of >=50 and <400 Gi/L 6 months Overall response: either a durable response or a transient platelet response 6 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate eltrombopag and romiplostim in thrombopoietin receptor activation for ITP?
How does eltrombopag's efficacy in ITP compare to romiplostim when benchmarked against standard-of-care thrombopoietin receptor agonists?
Which biomarkers correlate with platelet response or reduced bleeding events in eltrombopag vs romiplostim for immune thrombocytopenia?
What adverse event profiles distinguish eltrombopag and romiplostim in GlaxoSmithKline's observational ITP trial NCT01236014?
Are there combination therapies involving eltrombopag or romiplostim that enhance outcomes in refractory immune thrombocytopenic purpura?